For US Healthcare Professionals Only
For US Healthcare Professionals Only
aAs of the 3-month data cutoff.2
bNational Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.1
cThe Infections category included any terms in the Medical Dictionary for Regulatory Activities that were site or organ specific (eg, urinary tract, lung).2
dThese categories included any infections that were attributed to a particular organism, regardless of the site of infection (eg, Clostridium difficile, cytomegalovirus, BK virus).2
aAs of the 3-month data cutoff.2
bNational Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.1
aThe safety population included all patients who received at least 1 dose of study therapy.3
bA distinction between cytomegalovirus infection and reactivation was not made in this study.3
Although the AE data reported in REACH2 are informative, the risk information described in the Full Prescribing Information for Jakafi should be considered when making prescribing decisions.
AE=adverse event; ALT=alanine transaminase; AST=aspartate transaminase; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation.
References: 1. Jakafi [package insert]. Wilmington, DE: Incyte Corporation. 2. Data on file. Incyte Corporation. Wilmington, DE. 3. Zeiser R, von Bubnoff N, Butler J, et al; for the REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-1810. Supplementary appendix available at: https://www.nejm.org/doi/10.1056/NEJMoa1917635.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.